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Abstract
Aims/hypothesis Recent clinical studies have shown that renal
sympathetic denervation (RDX) improves glucose metabo-
lism in patients with resistant hypertension. We aimed to elu-
cidate the potential contribution of the renal sympathetic ner-
vous system to glucose metabolism during the development of
type 2 diabetes.
Methods Uninephrectomised diabetic Otsuka Long-Evans
Tokushima Fatty (OLETF) rats underwent RDX at 25 weeks
of age and were followed up to 46 weeks of age.
Results RDX decreased plasma and renal tissue noradrenaline
(norepinephrine) levels and BP. RDX also improved glucose
metabolism and insulin sensitivity, which was associated with
increased in vivo glucose uptake by peripheral tissues.
Furthermore, RDX suppressed overexpression of sodium-
glucose cotransporter 2 (Sglt2 [also known as Slc5a2]) in renal
tissues, which was followed by an augmentation of glycosuria
in type 2 diabetic OLETF rats. Similar improvements in
glucose metabolism after RDX were observed in young
OLETF rats at the prediabetic stage (21 weeks of age) without
changing BP.
Conclusions/interpretation Here, we propose the new con-
cept of a connection between renal glucose metabolism and
the renal sympathetic nervous system during the development
of type 2 diabetes. Our data demonstrate that RDX exerts
beneficial effects on glucose metabolism by an increase in
tissue glucose uptake and glycosuria induced by Sglt2 sup-
pression. These data have provided a new insight not only into
the treatment of hypertensive type 2 diabetic patients, but also
the pathophysiology of insulin resistance manifested by sym-
pathetic hyperactivity.
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Insulin resistance is a common feature of the metabolic
syndrome and type 2 diabetes, which is often associated
with sympathetic nervous system hyperactivity [1–3]. A
potential bidirectional relationship between sympathetic
hyperactivity and insulin resistance, hypertension, diabe-
tes or cardiovascular injury has also been suggested [4,
5]. Renal afferent and efferent nerves mediate a sympa-
thetic signal between the kidney and central sympathetic
nervous system, respectively [6, 7]. Obese and diabetic
patients show an increase in renal sympathetic nerve ac-
tivity, which is associated with hypertension, insulin re-
sistance and cardio-renal syndrome [6, 8, 9]. In patients
with heart failure, increases in noradrenaline (norepi-
nephrine [NE]) overflow from the heart and the kidney
were also observed [10].
Accumulating clinical evidence has indicated the ef-
fectiveness of catheter-based renal sympathetic denerva-
tion (RDX) in reducing BP [11–13] and left ventricular
hypertrophy [14]. We have demonstrated that RDX sup-
presses the onset of albuminuria in cardiac volume
overload rats [15], highlighting the importance of the
renal sympathetic nervous system in cardio-renal syn-
drome. SYMPLICITY HTN-3, a prospective, single-
blind, randomised clinical trial did not show a signifi-
cant systolic BP (SBP) reduction in patients with resis-
tant hypertension 6 months after renal-artery denervation
[16]. However, Mahfoud et al [17] have shown that
RDX improves glucose metabolism, insulin sensitivity
and BP control in patients with resistant hypertension
in the absence of any changes in body weight or life-
style. Furthermore, Witkowski et al [18] have shown
that RDX improves comorbid refractory hypertension,
glucose intolerance and obstructive sleep apnoea in pa-
tients with resistant hypertension. More interestingly, it
has also been demonstrated that RDX exerts beneficial
effects not only on BP control but also on insulin sen-
sitivity in polycystic ovary syndrome patients [19].
However, the mechanism responsible for the beneficial
effect of RDX on glucose metabolism has not yet been
clarified.
In the present study, we aimed to determine the pre-
cise mechanism by which the renal sympathetic nervous
system contributes to glucose metabolism during the de-
velopment of type 2 diabetes. Here, we demonstrated
that RDX markedly improved insulin sensitivity and
glucose metabolism by increasing glucose uptake in pe-
ripheral tissues of obese type 2 diabetic Otsuka Long-
Evans Tokushima Fatty (OLETF) rats. Interestingly, im-
provement in glucose metabolism was also associated
with suppression of sodium-glucose cotransporter 2
(Sglt2 [also known as Slc5a2]) overexpression in the
kidney, leading to enhanced glycosuria. Similar data
were observed in young obese OLETF rats at the pre-
diabetic stage. These data suggest the novel concept of
a connection between renal glucose metabolism and the
renal sympathetic nervous system, which offers new in-
sight into the management of hypertensive patients with
obesity, the metabolic syndrome and type 2 diabetes.
Methods
Animals
Experimental protocols and animal care were performed
according to the guidelines for the care and use of an-
imals established by Kagawa University, Japan. Four-
week-old male obese OLETF and control lean Long-
Evans Tokushima Otsuka (LETO) rats (Hoshino
Laboratory, Bando, Japan) were maintained under a con-
trolled temperature (24±2°C) and humidity (55±5%),
with a 12 h light/dark cycle. Previous studies have
shown that OLETF rats exhibit the prediabetic metabo-
lic syndrome phase from 10 to 20 weeks of age, and
the type 2 diabetic phase from 25 to 30 weeks of age
[20, 21]. Thus, in this study, experiments of protocols 1
and 2 were conducted in OLETF rats at the diabetic
stage (from 25 to 46 weeks of age) and the prediabetic
stage (4 to 21 weeks of age).
Experimental protocols
Protocol 1 All rats were subjected to right uninephrectomy
under isoflurane anaesthesia at 5 weeks of age. Then, left
kidney RDX was performed at 25 weeks of age and rats
were grouped as follows: uninephrectomised control lean
LETO rats (LETO, n=10), uninephrectomised-denervated
LETO rats (LETO+RDX, n=10), uninephrectomised
OLETF rats (OLETF, n= 10), uninephrectomised-
denervated OLETF rats (OLETF+RDX, n=10). In proto-
col 1, OGTT was performed at 30, 35 and 45 weeks of
age (5, 10 and 20 weeks after RDX, respectively).
Twenty-four hour urine samples were collected to deter-
mine urinary NE, glucose and protein excretion. Fasting
blood glucose and body weight were measured at 25, 30,
35, 40 and 45 weeks of age.
Protocol 2 The rats were subjected to right unine-
phrectomy at 5 weeks of age. Left kidney RDX was
performed at 6 weeks of age and rats were grouped as
follows: LETO (n=8), LETO+RDX (n=8), OLETF (n=
8), OLETF+RDX (n=8). In both protocols 1 and 2,
right uninephrectomy was performed to prevent reno-
renal reflexes from the right kidney, as previously
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described [22, 23]. In protocol 1, OGTT was performed
at 14 and 20 weeks of age (8 and 14 weeks after RDX,
respectively). Twenty-four hour urine samples were col-
lected at 13, 17 and 20 weeks of age. Fasting blood
glucose and body weight were measured at 5, 9, 14,
18 and 20 weeks of age.
RDX
Uninephrectomised rats were subjected to RDX under
isoflurane anaesthesia. Complete RDX was achieved
by carefully cutting and stripping all of the visible renal
nerves along the renal artery and vein from the aorta to
the hilum of the kidney, and painting these vessels with
a solution of 10% phenol in ethanol (vol./vol.) [15, 24].
This method ablates the afferent and efferent renal
nerves [24, 25]. At the end of each experiment, renal
tissue was harvested and NE content was measured to
confirm the completeness of RDX [24, 25]. In both
protocols 1 and 2, the kidney NE content in all renal
denervated rats was almost undetectable (<5 ng/g tissue)
(Fig. 1a and Electronic Supplementary Material [ESM]
Fig. 1a).
OGTTand hyperinsulinaemic–euglycaemic clamp study
OGTT and hyperinsulinaemic–euglycaemic clamp studies
were performed as described previously [26–29]. Details are
provided in the ESM Methods.
Telemetric sensor implantation
BP profile (mean arterial pressure [MAP], SBP and
diastolic BP [DBP]) and heart rate were assessed by
radio-telemetry system (Data Sciences International, St
Paul, MN, USA) in conscious rats, as described pre-
viously [30, 31] in a separate set of animals (n=5 for
each treatment group). Details are provided in the ESM
Methods.
Measurement of rate constant of net tissue uptake
of 2-[3H]deoxy-D-glucose
In vivo uptake of 2-[3H]deoxy-D-glucose (2-[3H]DG) in
peripheral tissues (Brown adipose tissue [BAT], retro-
peritoneal white adipose tissues [WAT], skeletal muscles
[soleus muscles] and liver) was measured as described
previously [32, 33] in another group of animals (n=6
for each treatment group). The rate constant of net tis-
sue uptake of 2-[3H]DG was calculated, as described
previously [34]. Details are provided in the ESM
Methods.
Sample collection
At the end of each observation period, blood was collected
and kidneys perfusedwith an isotonic saline under anaesthesia
with sodium pentobarbital (65 mg/kg, i.p.). Details are pro-
vided in the ESM Methods.
Histological examination
Kidney tissues were fixed with 10% paraformaldehyde
(wt/vol.), embedded in paraffin, sectioned into 4 μm
thick slices and stained with periodic acid-Schiff
(PAS) [35, 36]. The percentage of PAS-positive areas
was measured us ing image analys is sof tware ,
WinROOF (Mitani Corporation, Tokyo, Japan). A total
of 25–30 glomeruli were examined per rat and the
average percentage of affected lesions was calculated
[35, 36].
Real-time RT-PCR
The mRNA expression in renal cortical tissues was
analysed by RT-PCR using a LightCycler FastStart
DNA Master SYBR Green I kit and an ABI Prism 7,
000 Sequence Detection System (Applied Biosystems,
Foster City, USA) as previously described [15, 35].
The oligonucleotide primer sequences for rat and human
are listed in ESM Tables 1 and 2, respectively. All data
from in vivo studies are expressed as the relative diffe-
rence in expression compared with LETO rats after nor-
malisation for β-actin expression. Data from in vitro
studies are expressed as the relative difference in ex-
pression compared with 5 mmol/l glucose after normali-
sation for β-actin expression.
Immunohistochemistry for sodium-glucose
cotransporter 2
Renal tissue fixation and immunofluorescence study for
Sodium-glucose cotransporter 2 (SGLT2) were performed as
described previously [37]. Details are provided in the ESM
Methods.
Other analytical procedures
Details are provided in the ESM Methods.
Cell culture experiments
HK2 cells (immortalised human kidney proximal tubule
epithelial cells) were cultured in DMEM supplemented
with 10% FBS [15]. After reaching 40% confluence in
a six-well plate, cells were serum deprived for 24 h
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before experimental manipulation. All experiments were
performed under serum-free conditions and the cells
remained viable in this condition in a nonproliferating
state. Quiescent cells were then treated with normal
glucose medium (5 mmol/l) as well as high glucose
(15 mmol/l) medium with or without 100 nmol/l NE
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Statistical analyses
The data are expressed as means ± SEM. Statistical compari-
sons of differences among groups were performed using one-
way repeated-measures ANOVA, followed by the Newman–
Keuls post hoc test. SBP, DBP, urinary protein excretion, uri-
nary glucose excretion, urinary NE excretion, fasting blood
glucose, HbA1c and body weight were compared using two-
way repeated-measures ANOVA followed by the same post
hoc test. Values of p<0.05 were considered statistically sig-
nificant. Data and statistical analyses were performed using
GraphPad Prism version 5 forWindows (Graph Pad Software,
San Diego, CA, USA).
Results
General variables and BP profiles
In both protocols 1 and 2, OLETF rats showed elevated renal
cortical tissue NE levels compared with age-matched LETO
rats. Kidney NE levels in all RDX rats were almost undetect-
able, indicating that RDX was successfully completed
(Fig. 1a, ESM Fig. 1a). Renal cortical tissue adrenaline levels
are elevated in OLETF rats in protocol 1 and were unaffected
by RDX in both protocols 1 and 2 (Table 1). During the
experimental period, OLETF rats had higher body weight
gain and daily food intake than LETO rats. RDX at dia-
betic or prediabetic stages did not affect daily food intake
and body weight gain either in LETO or OLETF rats
(Fig. 1b,c, ESM Fig. 1b,c). In both protocols 1 and 2,
fasting blood glucose and HbA1c were significantly higher
in OLETF than LETO rats, and were significantly de-
creased by RDX (Fig. 1d,e, ESM Fig. 1d,e). At 45 weeks
of age in protocol 1, the plasma insulin level was signif-
icantly higher in OLETF than LETO rats (1.03±0.13 and
33.46±2.7 pmol/l, p<0.0001, respectively), and was at-
tenuated by RDX in OLETF rats (20.90±6.1 pmol/l,
p<0.05). Both diabetic and prediabetic stage OLETF rats
have significantly higher plasma triacylglycerol, total cho-
lesterol and NEFA, which were suppressed by RDX (Tables 2
and 3). Plasma sodium and potassium levels were not altered by
RDX (Tables 2 and 3).
As shown in Fig. 1f–i and ESM Fig. 1f–i, SBP, MAP
and DBP were significantly higher in OLETF compared
with LETO rats, whereas heart rate did not differ among
the groups. In protocol 1, RDX significantly decreased
BP in OLETF rats, but not in LETO rats. There was a
trend towards lower heart rate in OLETF rats given
RDX, but these changes were not significant (Fig. 1f–i
for SBP, MAP, DPB and heart rate, respectively). In
contrast, in protocol 2, RDX did not significantly affect
the BP profiles of LETO and OLETF rats at prediabetic
stage (ESM Fig. 1f–i for SBP, MAP, DPB and heart
rate, respectively). Further details are provided in the
ESM Results.
Glucose metabolism and insulin sensitivity
In protocol 1, OLETF rats showed significantly elevated
glucose and insulin levels after oral administration of glu-
cose compared with LETO rats. RDX attenuated increases
in glucose and insulin levels in OLETF rats. The AUC for
blood glucose and insulin was significantly greater in
OLETF rats, and was significantly suppressed by RDX
(Fig. 2a,b and Fig. 2c,d, respectively). Whole body insu-
lin sensitivity was measured using the hyperinsulinaemic–
euglycaemic clamp method and OLETF rats showed
Table 1 Kidney tissues adrena-
line levels at the diabetic stage
(protocol 1) and at the prediabetic
stage (protocol 2)
Diabetic stage (at 46 weeks of age);
adrenaline (ng/g wet tissue)
Prediabetic stage (at 21 weeks of age);
adrenaline (ng/g wet tissue)
LETO (n=8) 1.2±0.5 1.1±0.3
LETO+RDX (n=8) 1.8±0.4 0.9±0.5
OLETF (n=8) 4.9±0.9** 0.8±0.3
OLETF+RDX (n=8) 5.4±0.6 0.8±0.4
Data are means ± SEM
**p<0.01 LETO vs OLETF
Fig. 1 (a) OLETF rats show significantly higher kidney tissue NE levels
compared with LETO rats. Kidney tissue NE levels in OLETF rats
subjected to RDX are almost undetectable. (b, c) OLETF rats show
higher body weight (b) and daily average food intake (c) compared
with LETO rats, which were not affected by RDX. (d, e) OLETF rats
show markedly elevated fasting blood glucose (d) and HbA1c (e) levels
compared with LETO rats, which are suppressed by RDX. (To convert
values for HbA1c in DCCT% into mmol/mol, subtract 2.15 and multiply
by 10.929.) (f–h) OLETF rats show markedly increased SBP (f), MAP
(g) and DBP (h) compared with LETO rats. RDX suppresses SBP, MAP
and DBP in OLETF rats. However, heart rate was not different among the
groups (i). †p<0.05, ††p<0.01, †††p<0.005 LETO vs OLETF; ‡p<0.05,
‡‡p<0.01, ‡‡‡p<0.005 OLETF vs OLETF+RDX; §p<0.05 LETO vs
LETO+RDX; §§§p<0.005 LETO vs LETO+RDX. White bars and
white diamonds, LETO group; black bars and black circles, OLETF
group; light grey bars and black diamonds, LETO+RDX; dark grey
bars and white circles, OLETF+RDX
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significantly lowered glucose infusion rate (GIR) com-
pared with LETO rats, which was significantly increased
by RDX in OLETF rats (Fig. 3a).
OLETF rats showed significantly lowered in vivo glucose
uptake in glucose sensitive tissues such as BAT, WAT, soleus
muscle and liver compared with LETO rats. Notably, RDX
significantly increased glucose uptake by the peripheral tis-
sues in OLETF rats.
OLETF rats showed elevated plasma NE levels and in-
creased urinary NE excretion during the experimental period
compared with age-matched LETO rats (Fig. 3c,d, respective-
ly). RDX significantly attenuated both plasma NE levels and
urinary NE excretion. These results indicate that at the diabetic
stage, OLETF rats have sympathetic hyperactivity, which was
suppressed by RDX. In contrast, RDX markedly increased
urinary glucose excretion in both LETO and OLETF rats
(Fig. 3e).
In protocol 2, data with a similar glucose metabolism trend
to protocol 1 were observed in protocol 2, as shown in ESM
Fig. 2a–d and ESM Fig. 3a–e. Further details are provided in
the ESM Results.
Glucose transporters in the kidney
In protocol 1, renal cortical tissue Glut1 (also known as
Slc2a1) mRNA levels were similar among the different
treatment groups (Fig. 4a). However, Sglt1 and Glut2 (also
known as Slc2a2) mRNA levels were slightly, but signifi-
cantly, increased in OLETF rats as compared with LETO
rats (Fig. 4b,c, respectively). Furthermore, the Sglt2
mRNA level was markedly upregulated in renal cortical
tissue of OLETF compared with LETO rats (Fig. 4d).
Increases in Sglt2 mRNA levels in OLETF rats were sig-
nificantly decreased by RDX.
Immunohistochemical SGLT2 staining was stronger in
OLETF as compared with LETO and OLETF+RDX rats
(Fig. 4e). These results showed that in diabetic OLETF rats,
renal Sglt2 expressionwas upregulated, which was suppressed
by RDX. Thus, RDX-induced suppression of renal Sglt2
expression may lead to reduction in proximal tubular glucose
reabsorption, resulting in an increase in urinary glucose
excretion.
In protocol 2, similar data on glucose transporter
gene and protein expression in the kidney were obtained
(ESM Fig. 4a–g). Further details are provided in the ESM
Results.
Glucose transporters expression in the skeletal muscle
The levels of Glut4 (also known as Slc2a4) expression
were significantly decreased in the skeletal muscle (soleus
muscle) of diabetic (OLETF) rats when compared with
control rats (LETO) (ESM Table 3). However, subjecting
OLETF rats to RDX restored the expression of Glut4 in
the skeletal muscle when compared with untreated diabe-
tic (OLETF) rats. Subjecting LETO rats to RDX produced
no significant changes in the expression of Glut4 in skele-
tal muscle when compared with normal control (LETO)
Table 3 Plasma lipid and elec-
trolyte profiles at the prediabetic
stage (21 weeks of age, protocol
2)
LETO (n=8) LETO+RDX (n=8) OLETF (n=8) OLETF+RDX (n=8)
Triacylglycerol (mmol/l) 0.40±0.03 0.32±0.03 1.73±0.13††† 0.89±0.03**
Total cholesterol (mmol/l) 2.1±0.02 1.9±0.05 2.7±0.08†† 2.1±0.07**
NEFA (mmol/l) 0.43±0.02 0.41±0.01 0.80±0.02††† 0.51±0.01**
Sodium (mmol/l) 133.6±1.9 132.0±2.0 138.5±1.3 134.5±1.0
Potassium (mmol/l) 6.5±0.3 6.0±0.1 6.1±0.2 5.7±0.1
**p<0.01 OLETF vs OLETF+RDX; †† p<0.01, ††† p<0.005 LETO vs OLETF
Table 2 Plasma lipid and elec-
trolyte profiles at the diabetic
stage (46 weeks of age,
protocol 1)
LETO (n=8) LETO+RDX (n=8) OLETF (n=8) OLETF+RDX (n=8)
Triacylglycerol (mmol/l) 0.56±0.03 0.50±0.07 5.71±.059††† 3.01±0.56‡‡‡
Total cholesterol (mmol/l) 2.71±0.06 1.90±0.07* 5.93±0.18†† 4.11±0.37‡‡
NEFA (mmol/l) 0.35±0.03 0.28±0.04 0.84±0.07†† 0.47±0.03‡‡
Sodium (mmol/l) 141.0±0.8 139.0±0.7 154.0±2.0† 145.0±1.2
Potassium (mmol/l) 6.5±0.3 6.4±0.1 6.6±0.3 6.0±0.3
Data are means±SEM
*p<0.05 LETO vs LETO+RDX; † p<0.05, †† p<0.01, ††† p<0.005 LETO vs OLETF; ‡‡ p<0.01, ‡‡‡ p<0.005
OLETF vs OLETF+RDX
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Fig. 2 (a–f) Blood glucose levels
and their respective AUCs at 30
(a, b), 35 (c, d) and 45 (e, f) weeks
of age during OGTT. OLETF rats
show higher glucose levels and
AUCs, which are suppressed by
RDX. (g–l) Plasma insulin levels
and their AUC at 30 (g, h), 35
(i, j) and 45 (k, l) weeks of age.
OLETF rats show higher plasma
insulin levels and AUC, which
were suppressed by RDX.
†††p<0.005 LETO vs OLETF;
‡p<0.05, ‡‡p<0.01, OLETF vs
OLETF+RDX; §p<0.05, LETO
vs LETO+RDX. White bars and
white diamonds, LETO group;
black bars and black circles,
OLETF group; light grey bars and
black diamonds, LETO+RDX;
dark grey bars and white circles,
OLETF+RDX
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rats. Similar results were observed in prediabetic stage
rats as shown in ESM Table 3.
Renal functional and histological changes
In protocol 1, OLETF rats developed proteinuria age-depen-
dently. RDX significantly reduced proteinuria in OLEFT rats
(Fig. 5a). Plasma creatinine concentration was significantly
higher in OLETF rats compared with LETO rats, which was
lowered by RDX (Fig. 5b). Renal cortical sections showed
increased glomerular PAS-positive area in OLETF rats com-
pared with LETO rats. RDX significantly decreased glomer-
ular PAS-positive area (Fig. 5c,d).
In protocol 2, OLETF rats showed proteinuria and in-
creased PAS-positive area compared with LETO rats.
However, RDX did not significantly affect these variables
(ESM Fig. 5a–d) at the prediabetic stage. Further details are
provided in the ESM Results.
Cell culture experiments
To further confirm the possible contribution of sympathetic
nervous system to renal SGLT2 (also known as SLC5A2)
expression, we performed in vitro studies using immor-
talised human kidney proximal tubular epithelial HK2
cells. Treatment with high glucose for 12 h upregulated
SGLT2 mRNA expression, which was further enhanced
by exposure to NE (Fig. 6a). GLUT2 (also known as
SLC2A2) mRNA expression was also upregulated by high
glucose treatment, and was further enhanced by exposure
to NE (Fig. 6b). In contrast, SGLT1 (also known as
SLC5A1) and GLUT1 (also known as SLC2A1) mRNA
expressions remained unaltered after high glucose and/or
high glucose plus NE treatment (Fig. 6c,d). Similarly,
exposure to high glucose plus NE for 24 h significantly
upregulated SGLT2 gene expression in HK2 cells (ESM
Fig. 6a–d).
Discussion
In the present study, we demonstrate that during the
development of type 2 diabetes, RDX attenuates syste-
mic and regional sympathetic hyperactivity, and substan-
tially reduces glucose intolerance and insulin insensiti-









































































































































































Fig. 3 (a) OLETF rats show lower GIR during the hyperinsulinaemic–
euglycaemic clamp study, which is increased by RDX. (b) During rate
constant net tissue uptake of 2-[3H]DG measurement, OLETF rats show
lower glucose uptake in BAT, WAT, soleus muscles and liver tissues
compared with LETO rats. RDX improves glucose uptake by these tis-
sues in OLETF rats. (c, d) OLETF rats show elevated plasma NE levels
(c) and urinary NE excretion (d), which are suppressed by RDX. (e)
OLETF rats show higher urinary glucose excretion, which is further in-
creased by RDX. †p<0.05, ††p<0.01, †††p<0.005 LETO vs OLETF;
‡p<0.05, ‡‡p<0.01, ‡‡‡p<0.005 OLETF vs OLETF+RDX; §p<0.05
LETO vs LETO+RDX. White bars, LETO group; black bars, OLETF
group; light grey bars, LETO+RDX; dark grey bars, OLETF+RDX
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improvement of glucose uptake by peripheral tissues;
and (2) enhancement of urinary glucose excretion by
suppression of renal Sglt2 overexpression.
A growing body of evidence indicates there is inappro-
priate activation of the sympathetic nervous system during
the development of insulin resistance [38], the metabolic
syndrome [39] and diabetes [5, 8]. Sympathetic hyperac-
tivity could be responsible for lower glucose uptake by
peripheral tissues, due to a reduction in blood flow with
increased peripheral NE release [40]. A direct relationship
between muscle sympathetic hyperactivity and insulin re-
sistance has also been indicated [41]. In the present study,
obese type 2 diabetic and prediabetic OLETF rats showed
a reduction in tissue glucose uptake with systemic sym-
pathetic hyperactivity as confirmed by increases in plasma
and urine NE levels. Furthermore, RDX decreased sys-
temic NE levels and improved tissue glucose uptake in
these animals. Thus, the present data are consistent with
concepts based on previous clinical studies [17, 18],
namely that the systemic sympathetic nervous system
plays an important role in glucose metabolism by regula-
ting tissue glucose uptake during the development of type
2 diabetes.
It has also been suggested that insulin acts as a po-
tential mediator of sympathetic overdrive in hyperten-
sion and other cardiovascular complications [1, 3].
Alternatively, intrarenal sympathetic hyperactivity may
cause increased renal afferent nerve signalling leading
to further stimulation of the central sympathetic nervous
system, thus initiating a vicious cycle (Fig. 7a). RDX
breaks this vicious cycle resulting in suppression of the
sympathetic nervous system, and thereby improved glu-
cose metabolism and insulin sensitivity in obese type 2
diabetic rats (Fig. 7b). These data suggest an interaction
among insulin resistance, obesity and the central ner-
vous system. The most plausible interpretation of the
above results is in clinical use of a centrally acting
sympatholytics drug, which is known to reduce central
sympathetic activity [42], reduce efferent sympathetic
nerve traffic to the kidney, and suppress glucose intole-
rance and increase skeletal muscle blood flow with less
glycogenolysis [1, 43]. Although centrally acting sym-
patholytics have some beneficial effects in clinics [44,
45], these drugs are nonspecific and limited by their
adverse effects on insulin resistance and an unawareness
of hypoglycaemia in patients with diabetes [45].
Adverse effects of blockade of β2-receptors on glucose
metabolism have also been recognised [46, 47]. In con-
trast to nonselective β-blockers, β1-selective blockers
appear to be without relevant influence on glucose me-
tabolism [47, 48]. However, in some studies, adverse
effects of β1-selective β-blockers have been described
[49]. Glycogenolysis and gluconeogenesis in liver are
stimulated through β2-receptors [50]. Blockade of these
receptors could prolong recovery-time from hypo-
glycaemia. Under nonselective β-blocker treatment, such
prolongation of hypoglycaemia has been described [51].
Therefore, suppressing the sympathetic nervous system
directly by RDX seems to be a better option for diabe-
tes. Furthermore, hypertension, glucose intolerance and
insulin insensitivity regularly coincide, with sympathetic
hyperactivity being an obvious but not the only link
among these, but also other pathological conditions [2].
The potential role of the kidney in the regulation of
blood glucose levels has been well documented in ear-
lier studies [52]. SGLT2 is a high-capacity, low-affinity
glucose transporter located in the early convoluted
segment of the renal proximal tubule, where luminal
glucose is abundant [53–55]. SGLT2 reabsorbs































































































Fig. 4 (a) Glut1 mRNA levels are similar among the treatment groups.
(b, c) Sglt1 (b) and Glut2 (c) mRNA expression is upregulated. (d) Sglt2
mRNA level is markedly upregulated in OLETF rats, which is suppressed
by RDX. (e) Immunofluorescence micrographs of staining with anti-
SGLT2 antibody (red fluorescence) (original magnification, ×200). The
staining intensity is weaker in OLETF+RDX than OLETF. All mRNA
data are expressed as the relative difference in expression compared with
LETO rats after normalisation for β-actin expression. †p<0.05,
†††p<0.005 LETO vs OLETF; ‡p<0.05, ‡‡p<0.01 OLETF vs.
OLETF+RDX.White bars, LETO group; black bars, OLETF group; light
grey bars, LETO+RDX; dark grey bars, OLETF+RDX
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approximately 90% of filtered renal glucose [56, 57] by
coupling glucose transport to the electrochemical sodi-
um gradient [53–55]. SGLT2 inhibitors reduce renal
glucose reabsorption and promote urinary glucose excre-
tion, thus lowering glucose blood levels. In the present
study, renal Sglt2 gene and SGLT2 protein levels were
significantly increased in obese type 2 diabetic OLETF
rats. Interestingly, the present study also demonstrated
for the first time that RDX attenuates Sglt2 overexpres-
sion in the kidney. These findings are consistent with
the concept that during the development of type 2 dia-
betes, intrarenal sympathetic hyperactivity enhances
renal Sglt2 expression, resulting in increased glucose
reabsorption. This concept was further evaluated by an
in vitro cell culture study. In cultured human proximal
tubular HK2 cells, high glucose conditions significantly
increased SGLT2 gene expression, which was further
augmented by treatment with NE. Collectively, the pre-
sent study demonstrates that RDX improves glucose me-
tabolism by inhibiting inappropriately augmented renal
Sglt2 expression, and results in a subsequent glycosuria
during the development of type 2 diabetes. These data
suggest that RDX is a logical approach not only for the

















































































LETO OLETF OLETF + RDXLETO + RDX
c
Fig. 5 (a) OLETF rats show
overt proteinuria, which is
reduced by RDX. (b) Plasma
creatinine concentration was
slightly elevated in OLETF rats
and is attenuated by RDX. (c)
Representative micrographs of
PAS-stained renal sections. (d)
PAS-positive area within the total
glomerular area. RDX partially
reduced PAS-positive area.
†p<0.05, †††p<0.005,
††††p<0.001 LETO vs OLETF;
‡p<0.05, ‡‡p<0.01 OLETF vs
OLETF+RDX. Scale bar, 50 μm.
White bars, LETO group; black
bars, OLETF group; light grey
bars, LETO+RDX; dark grey
bars, OLETF+RDX
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also for other clinical adverse consequences manifested
by sympathetic hyperactivity. Furthermore, Dominik
Linz et al [5] previously reported the effects of RDX
in SHRs-ob rats when hypertension, the metabolic syn-
drome and nephropathy are already established, and
showed that even at this later stage of renal and cardiac
remodelling, RDX attenuated the further progression of
hypertension, renal and cardiac damage, suggesting the
pivotal role of renal sympathetic activation in these
pathophysiological conditions and of RDX for the man-
agement of diabetes in obese spontaneously hyperten-
sive rats. However, there are some limitations of current
clinical studies for RDX. First, the SYMPLICITY HTN-
3 clinical trial did not show significant reduction in BP
in resistant hypertensive patients in a randomised, con-
trolled trial [16]. Moreover, the finding that RDX im-
proves glucose metabolism in resistant hypertensive pa-
tients [17, 18] has not been confirmed in controlled trials
and has not been separated from its BP-lowering effects.
In the present study, there are several limitations as it
is still unclear that the beneficial effects of RDX are due
to ablation of renal efferent vs afferent nerves. It is im-
portant to note that glucose tolerance, insulin sensitivity
and urinary protein excretion are still high in rats
subjected to RDX compared with control rats. This may
be due to other known factors [2] that are involved in
insulin resistance in this model. Alternatively, it is pos-
sible that the degree of diabetes is too severe to fully
reverse changes by RDX. Further studies are needed to
address such issues.
We previously showed that RDX did not change BP in rats
subjected to aortic regurgitation, but elicited beneficial effects
on cardio-renal syndrome [15]. Other studies have also sug-
gested that RDX ameliorates the incidence of stroke and brain
injury in hypertensive rats, independent of BP changes [58].
In the present study, RDX decreased BP and improved glu-
cose metabolism in type 2 diabetic OLETF rats. However, in
prediabetic animals, RDX also significantly improved insulin
resistance without changing BP. These data suggest that the
beneficial effects of RDX on glucose intolerance and insulin
resistance cannot be explained solely by its BP-lowering
effects.
Conclusions
Here, we propose the novel concept of a connection
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‡
‡Fig. 6 (a) Treatment with high
glucose for 12 h upregulated
SGLT2 mRNA expression, which
was further enhanced by exposure
to NE in HK2 human kidney
proximal tubule epithelial cells.
(b) GLUT2 mRNA expression
was also upregulated by high
glucose treatment, and was
further enhanced by exposure to
NE. (c, d) In contrast, SGLT1 (c)
and GLUT1 (d) mRNA
expression remained unaltered
after high glucose and/or high
glucose plus NE treatment. Data
are expressed as the relative
difference in expression
compared with 5 mmol/l glucose
after normalisation for β-actin
expression. *p<0.05, **p<0.01
vs 5 mmol/l glucose; ¶¶p<0.01 vs
5 mmol/l glucose + NE; †p<0.05
vs 15 mmol/l glucose. ‡p<0.05,
as indicated
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nervous system (Fig. 7a). The activities of the systemic
nervous system and renal SGLT2 are regulated by affer-
ent and efferent renal nerve activities, respectively, both
of which contribute to glucose intolerance and insulin
resistance during the development of type 2 diabetes.
RDX results in a suppression of the sympathetic ner-
vous system and subsequent improvement of glucose
metabolism (Fig. 7b). Thus, the present data may
provide a new insight not only into the treatment of
hypertensive diabetic patients, but also the pathophy-
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Fig. 7 (a) Schematic diagram
summarising the proposed
mechanisms by which renal
sympathetic nerves contribute to
glucose metabolism during the
development of type 2 diabetes.
(b) Effects of RDX on renal
glucose metabolism. CNS, central
nervous system, SNS;
sympathetic nervous system
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